Close Menu

Insilicos

The $800,000 is part of a convertible bridge note agreement that could provide Insilico at least $4M in a next funding round, based on certain milestones.

Insilicos, a Seattle-based biomedical software company, is partnering with the University of Washington to market a cloud-based version of the university’s Rosetta protein and molecular modeling software.

The plan, which the agency made public on Jan. 19, detailed a number of draft guidances FDA intends to put out this year; but it's the items that it declined to address, like the development of a new Class IIb device category, that could be the most significant.

Movers & Shakers: Dec 24, 2010

Premium

Peter Bergquist, John Fletcher, Lars Utterman, David Weber, Jeff Howbert

The patent follows on one the company received last year for the Erenna platform itself, and comes as it begins efforts to develop the assay as a clinical diagnostic that it hopes to submit for US Food and Drug Administration approval within the next two years.

A number of prominent proteomics-based diagnostics developers were recipients of the grant and tax credit awards, which are being provided by the IRS through the Patient Protection and Affordable Care Act's Qualifying Therapeutic Discovery Project Program.

Building on the results of a 38-patient study published in July, the company hopes to develop its PreClue cardiovascular disease biomarker panel as a clinical diagnostic for either screening or treatment-planning purposes.

Entelos, GlaxoSmithKline, Insilicos, Sciformatix, E&K, EMBL, Genomatix, Fox Chase Cancer Center, BioDiscovery, Roche, Genedata

The $400,000 grant will go to develop a statistical method used for making data-based predictions about diseases.

Funding from the National Institutes of Health for all proteomics-related research shrank by almost 3 percent in fiscal 2008, according to an analysis of NIH data by ProteoMonitor.

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.